ABSTRACT
The COVID-19 pandemic has highlighted the need for rapid and reliable diagnostics that are accessible in resource-limited settings. To address this pressing issue, we have developed a rapid, portable, and electricity-free method for extracting nucleic acids from respiratory swabs (i.e.nasal, nasopharyngeal and buccal swabs),successfully demonstrating its effectiveness for the detection of SARS-CoV-2 in residual clinical specimens. Unlike traditional approaches, our solution eliminates the need for micropipettes or electrical equipment, making it user-friendly and requiring little to no training. Our method builds upon the principles of magnetic bead extraction and revolves around a low-cost plastic magnetic lid, called SmartLid, in combination with a simple disposable kit containing all required reagents conveniently pre-aliquoted. Here, we clinically validated the SmartLid sample preparation method in comparison to the gold standard QIAamp Viral RNA Mini Kit from QIAGEN, using 406 clinical isolates, including 161 SARS-CoV-2 positives, using the SARS-CoV-2 RT-qPCR assays developed by the US Centers for Disease Control and Prevention (CDC). The SmartLid method showed an overall sensitivity of 95.03% (95% CI: 90.44%–97.83%) and a specificity of 99.59% (95% CI: 97.76%–99.99%), with a positive agreement of 97.79% (95% CI: 95.84%–98.98%) when compared to QIAGEN’s column-based extraction method. There are clear benefits to using the SmartLid sample preparation kit: it enables swift extraction of viral nucleic acids, taking less than 5 minutes, without sacrificing significant accuracy when compared against more expensive and time-consuming alternatives currently available on the market. Moreover, its simplicity makes it particularly well-suited for the point-of-care where rapid results and portability are crucial. By providing an efficient and accessible means of nucleic acid extraction, our approach aims to introduce a step-change in diagnostic capabilities for resource-limited settings.
Competing Interest Statement
IP, MLC, KMC, KTM, NM, PG and JRM have financial interest on ProtonDx Ltd, which currently has an exclusive license to the SmartLid intellectual property and trademark. All authors declare that they have no other conflict of interest related to this work. All the authors declare that they do not have any other known competing financial interests or person-al relationships that could have appeared to influence the work reported in this paper.
Funding Statement
This work was supported by the Department of Health and Social Care-funded Centre for Antimicrobial Optimisation (CAMO) at Imperial College London; The Imperial College 3M/Global Giving Foundation COVID-19 Research Award; and the Imperial COVID-19 Research Fund. IP acknowledges the NIH Research award (WMNP_P61895) at Imperial College London. AH, PG and JRM are affiliated with the NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London in partnership with the UK Health Security Agency, in collaboration with, Imperial Healthcare Partners, the University of Cambridge and the University of Warwick. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care, or the UK Health Security Agency. AH is a National Institute for Health Research (NIHR) Senior Investigator.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) with NHS Research Ethics Committee (REC) reference 20/HRA/1561.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors